News
THMO
0.2399
-13.05%
-0.0360
Looking Into ThermoGenesis Holdings's Return On Capital Employed
According to Benzinga Pro data, during Q1, ThermoGenesis Holdings (NASDAQ:THMO) posted sales of $2.66 million. Earnings were up 29.45%, but ThermoGenesis Holdings still reported an overall loss of $2.04 million.
Benzinga · 06/23 14:04
55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
Benzinga · 06/15 16:14
BRIEF-Thermogenesis Holdings Announces Financial Results For The First Quarter Ended March 31, 2022 And Provides Corporate Update
reuters.com · 05/19 21:25
ThermoGenesis GAAP EPS of -$0.16, revenue of $2.66M
ThermoGenesis press release (NASDAQ:THMO): Q1 GAAP EPS of -$0.16. Revenue of $2.66M (+75.0% Y/Y).
Seekingalpha · 05/19 20:17
ThermoGenesis Holdings Q1 EPS $(0.16) Misses $0.02 Estimate, Sales $2.70M May Not Compare To $5.60M Estimate
ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $0.02 by 900 percent. This is a 40.74 percent increase over losses of $(0.27) per share
Benzinga · 05/19 20:06
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/19 12:01
Earnings Scheduled For May 19, 2022
  Companies Reporting Before The Bell • Sociedad Quimica Y Minera (NYSE:SQM) is projected to report quarterly earnings at $1.28 per share on revenue of $1.28 billion.
Benzinga · 05/19 08:50
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 ...
PR Newswire · 05/18 12:30
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) About To Shift From Loss To Profit
We feel now is a pretty good time to analyse ThermoGenesis Holdings, Inc.'s ( NASDAQ:THMO ) business as it appears the...
Simply Wall St. · 05/15 14:58
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:25
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 23:15
24 Stocks Moving in Wednesday's Pre-Market Session
Gainers
Benzinga · 03/30 11:40
ThermoGenesis stock down 16% on FY revenue miss
ThermoGenesis (THMO -15.9%) reported lower-than-expected 2021 revenue, hurt by fall in sales of CAR-TXpress platform. The company's FY revenue fell ~5% to $9.29M, missing estimates by $0.96M. Selling, general and administrative
Seekingalpha · 03/29 16:30
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.
Benzinga · 03/29 09:11
ThermoGenesis GAAP EPS of -$0.96 misses by $0.16, revenue of $9.29M misses by $0.96M
ThermoGenesis press release (NASDAQ:THMO): FY GAAP EPS of -$0.96 misses by $0.16. Revenue of $9.29M (-4.6% Y/Y) misses by $0.96M. Shares -5.5%.
Seekingalpha · 03/28 20:21
ThermoGenesis Holdings FY21 EPS $(0.96) Up From $(2.60) YoY, Sales $9.30M Down From $9.70M YoY
ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.96) per share. This is a 63.08 percent increase over losses of $(2.60) per share from the same period last year. The company reported $9.30 million
Benzinga · 03/28 20:11
Earnings Scheduled For March 28, 2022
  Companies Reporting Before The Bell • LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million.
Benzinga · 03/28 08:45
Notable earnings after Monday's close
CYCC, DNA, EGLX, EYEN, HNRG, IONQ, LIDR, MBII, PLAY, OTCQX:PLNHF, PROG, RSLS, THMO, WYY, XOS, ZEV For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 03/27 21:35
ThermoGenesis Holdings's Earnings: A Preview
ThermoGenesis Holdings (NASDAQ:THMO) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that ThermoGenesis Holdings will report an earnings per share (EPS...
Benzinga · 03/25 14:09
More
Webull provides a variety of real-time THMO stock news. You can receive the latest news about Thermogenesis Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About THMO
ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for chimeric antigen receptor- T (CAR-T) and other cell-based therapies. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for large scale cell manufacturing services. It manufactures and markets three categories of products, Clinical Bio-Banking Applications, Point-of-Care Applications, and Large Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications includes AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Point-of-Care Applications includes PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory useand CAR-TXpress Platform for clinical manufacturing.